Provided by Tiger Trade Technology Pte. Ltd.

PTC Therapeutics

69.45
-1.2500-1.77%
Post-market: 69.450.00000.00%16:10 EST
Volume:851.78K
Turnover:59.71M
Market Cap:5.58B
PE:7.77
High:72.00
Open:70.95
Low:69.30
Close:70.70
52wk High:87.50
52wk Low:35.95
Shares:80.29M
Float Shares:65.01M
Volume Ratio:0.83
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):8.94
EPS(LYR):-4.7276
ROE:-7740.12%
ROA:25.70%
PB:-35.80
PE(LYR):-14.69

Loading ...

Earning Preview: PTC Therapeutics Q4 revenue is expected to increase by 19.03%, and institutional views are to be added

Earnings Agent
·
Feb 12

TD Cowen Remains a Hold on PTC Therapeutics (PTCT)

TIPRANKS
·
Feb 13

BUZZ-PTC Therapeutics falls after withdrawing muscle disorder drug marketing application

Reuters
·
Feb 13

PTC Therapeutics Withdraws Translarna NDA After FDA Feedback

TIPRANKS
·
Feb 13

PTC Therapeutics Inc - Withdraws Nda Resubmission for Translarna

THOMSON REUTERS
·
Feb 13

PTC Therapeutics Provides Regulatory Update on Translarna™

THOMSON REUTERS
·
Feb 13

PTC Therapeutics Inc - Withdrawal Following FDA Feedback on Application Review

THOMSON REUTERS
·
Feb 13

PTC Therapeutics Inc. to Report Fourth Quarter and Full Year 2025 Financial Results

Reuters
·
Feb 05

PTC Therapeutics price target raised to $97 from $96 at BofA

TIPRANKS
·
Jan 30

Citi Keeps Their Hold Rating on PTC Therapeutics (PTCT)

TIPRANKS
·
Jan 30

PTC Therapeutics price target raised to $75 from $63 at TD Cowen

TIPRANKS
·
Jan 29

PTC Therapeutics Raised to Overweight From Equal-Weight by Barclays

Dow Jones
·
Jan 28

PTC Therapeutics assumed with Overweight from Equal Weight at Barclays

TIPRANKS
·
Jan 28

Does 2026 Revenue Guidance And Sephience Momentum Change The Bull Case For PTC Therapeutics (PTCT)?

Simply Wall St.
·
Jan 15

Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Revolution Medicines (RVMD) and West Pharmaceutical Services (WST)

TIPRANKS
·
Jan 13

PTC Therapeutics: Sephience Outperformance and Votoplam De‑Risking Drive Upgraded Medium-Term Growth Outlook and Buy Rating

TIPRANKS
·
Jan 13

Wave of Insider Moves as PTC Therapeutics Leaders Cash In on Company Stock

TIPRANKS
·
Jan 13

Christine Marie Utter, SVP and Chief Accounting Officer, Reports Disposal of PTC Therapeutics Inc. Common Shares

Reuters
·
Jan 13

PTC Therapeutics Exec VP and CLO Mark Elliott Boulding Reports Sale of Common Shares

Reuters
·
Jan 13

PTC Therapeutics Posts Strong 2025 Results, Updates 2026 Outlook

TIPRANKS
·
Jan 13